Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential.

The post FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy appeared first on MedCity News.